OBSEF.US ObsEva SA

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 16, 2026
Market cap
USD 11.7K
P/E
-
P/B
0.00x
ROE
-352.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2022.

Is OBSEF.US undervalued?

Graham number

The Graham number of ObsEva SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ObsEva SA fundamental analysis

No fundamental analysis for ObsEva SA yet.

ObsEva SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ObsEva SA

ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women's reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

Full company profile